Clinical trial
A Phase 2, Open-label, Clinical Trial of Fluoxetine, a Selective Serotonin Reuptake Inhibitor, in the Treatment of Pulmonary Arterial Hypertension
NCT03638908 is registered in ClinicalTrials.gov with University of Texas Southwestern Medical Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Open-label, Clinical Trial of Fluoxetine, a Selective Serotonin Reuptake Inhibitor, in the Treatment of Pulmonary Arterial Hypertension
- Lead sponsor
- University of Texas Southwestern Medical Center
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- November 30, 2013
- Completion date
- December 31, 2018
- Enrollment
- 8 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.